Emerging Therapies for the Management of Human Epidermal Growth Factor Receptor 2–/ERBB2-Altered Advanced Biliary Tract Cancers
Mené sur 32 patients atteints d'un cancer des voies biliaires HER2+ non résécable ou récidivant, cet essai multicentrique de phase II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité du trastuzumab déruxtécan après l'échec d'une chimiothérapie à base de gemcitabine
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.